Novo Nordisk's pricing strategies in the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, who's got accused the company of price gouging, mentioning the stark distinction among U.S. costs and those in Europe and copyright.In October 2024, Novo Nordisk released a research on scientific journal Character about a novel glucose-sens